Paradigm Biopharmaceuticals receives positive results for Ross River clinical trial
The trial was treating patients with joint pain or joint stiffness.
Company
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application. Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).
175 stories · page 2 of 2
Paradigm Biopharmaceuticals receives more positive real-world patient data
Doctors can administer the treatment to patients under the TGA Special Access Scheme.
Investments and investor services
S&P/ASX 200 set for positive start as US markets have Monday holiday
Monday is Memorial Day in the US meaning stock markets are closed.
Paradigm Biopharmaceuticals completes retail component of $26.3 million entitlement offer
The retail entitlement offer had a take-up rate of about 54.7% for acceptances of entitlements and applications for additional shares by eligible retail shareholders.
Paradigm Biopharmaceuticals completes institutional component of $26.3 million entitlement offer
Along with the entitlement offer, Paradigm has raised $51.6 million via a placement to professional, institutional and sophisticated investors.
Paradigm Biopharmaceuticals director buys shares on-market
The company has today commenced the retail component of its $77.9 million capital raising.
Paradigm Biopharmaceuticals secures $61.3 million in first stage of raising
The capital raising has attracted a number of international institutional investors.
Paradigm Biopharmaceuticals phase 2b trial achieves key endpoints in OA of the knee
OA remains the most common form of joint disease globally, affecting over 30 million adults in the US alone.
Paradigm Biopharmaceuticals raising $77.9 million to fund its pivotal phase 3 OA trial
In conjunction with the capital raise, Paradigm has revealed that it has successfully met the primary and secondary endpoints of its phase 2b trial in OA of the knee.
Paradigm Biopharmaceuticals gets a speeding ticket for 18% price increase
Over the past year, shares have come from 29 cents to be trading at around $1.90.
Paradigm Biopharmaceuticals director shows confidence with on-market share purchase
The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
Investments and investor services
Carnarvon Petroleum into S&P/ASX 300 – AC8, BGL, PAR into All Ordinaries
The rebalance changes are effective at the open of trading on March 18, 2019.
Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial
MPS or mucopolysaccharidoses is an orphan indication with market exclusivity and high profit margins.
Paradigm Biopharmaceuticals to court partners and licensees for OA drug commercialisation
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Paradigm Biopharmaceutical shares surge on clinical trial success
The trial met the primary endpoint with a change in the knee injury and OA outcome score, confirming the potential for safe and effective treatment with iPPS.
Paradigm Biopharmaceuticals to talk clinical trial results on conference call tomorrow morning
The call will discuss the phase IIb randomised double-blind placebo controlled multicentre study.
Paradigm Biopharmaceuticals has results pending for phase 2b clinical trial
A trading halt will remain in place until the start of trading on Tuesday, December 18, or when an announcement is released.
Paradigm Biopharmaceuticals chief executive Paul Rennie buys more shares
Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form
Paradigm Biopharmaceuticals gets more real world evidence of treatment success
Patients access the treatment through their doctor under the TGA’s Special Access Scheme.
Paradigm Biopharmaceuticals gains on market with upcoming clinical trial read-out, wider treatment potential
The readout of clinical trials is expected this month.
Paradigm Biopharmaceuticals ‘next Australian blockbuster biotech’, according to Fiftyone Capital
Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS) for orthopaedic treatment of OA and bone marrow edema lesions (BMEL).
Paradigm Biopharmaceuticals’ positive trial results potentially transformational, says Morgans research
The readout of clinical trial results is expected in December.
Paradigm Biopharmaceuticals signs agreement for use of iPPS in treatment of MPS
An exclusive licence agreement has been executed with the Icahn School of Medicine at Mount Sinai, New York.
Paradigm Biopharmaceuticals boosts financial position with $2.32 million R&D tax rebate
The company’s capital position now stands at $10.5 million which provides for the preparation of regulatory filings.
Paradigm Biopharmaceuticals enters agreement to treat US-based sportspeople
The partnership with the US-based network will give Paradigm substantial exposure and access to a large patient pool.
Paradigm Biopharmaceuticals secures $9 million to accelerate phase III
The company is focused on repurposing PPS, an FDA approved drug.
Paradigm Biopharmaceuticals enters trading halt ahead of capital raising
Shares in the drug development company last traded at 73 cents before the halt.
Paradigm Biopharmaceuticals finalises Ross River virus trial recruitment
Shares in the company have more than tripled over the past 12 months.
Paradigm Biopharmaceuticals new data shows 60% pain reduction, shares rise
Data is being collected through both a clinical trial and the TGA Special Access Scheme.
Paradigm Biopharmaceuticals completes recruitment for knee pain trial
The trial is being conducted at six sites in four states across Australia.
Paradigm Biopharmaceuticals’ leaping share price attracts ASX speeding ticket
Estimated size of the osteoarthritis treatment market is US$5 billion per annum.
Paradigm Biopharmaceuticals patients report over 50% pain reduction
These patients are being treated by their doctors under the TGA Special Access Scheme.
Paradigm Biopharmaceuticals osteoarthritis clinical trial ahead of schedule
The results readout for the study is expected during the December quarter this year.
Paradigm Biopharmaceuticals banking on near-term revenues from repurposing FDA approved drugs
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
XTEK appoints experienced investment executive to its board
Chris Fullerton has been appointed as a non-executive director.
Paradigm Biopharmaceuticals achieves pain treatment win with AFL players
Up to 50 AFL players at seven clubs are using the breakthrough pain treatment drug.
Paradigm Biopharmaceuticals’ osteoarthritis trial remains ahead of schedule
The company is repurposing the drug that has a long track record of treating inflammation.
Paradigm Biopharmaceuticals has success with PPS osteoarthritis treatment
Of 45 patients treated, 84.4% responded with a reduction in joint pain.
Paradigm Biopharmaceuticals adds AFL legend to list of osteoarthritis treatment wins
Paradigm is repurposing the drug that has a long track record of treating inflammation.
Paradigm Biopharmaceuticals eyes opportunities to treat osteoarthritis
Osteoarthritis affects as much as 13% of the world’s population.
Paradigm Biopharmaceuticals granted European patent
During 2018, Paradigm will release the results of its two phase II arthritis clinical trials.
Paradigm Biopharmaceuticals ahead of schedule with trials
The company is well advanced with two clinical trials aimed at diseases for which there are very few safe and effective drugs.
Paradigm Biopharmaceuticals meets primary endpoint in clinical trial
Paradigm aims to repurpose pentosan polysulfate sodium (PPS), an FDA-approved drug.
Paradigm Biopharmaceuticals funded into 2019 through placement
The placement was expanded due to strong demand from investors.
Paradigm Biopharmaceuticals to finalise raising
The halt will remain in place until Monday 6th November 2017.
Paradigm has successfully dosed first participant in clinical trial for osteoarthritis
The commencement of participant dosing follows ethics approval.
Paradigm reveals outcomes from patient case studies on Osteoarthritis
The Osteoarthritis market represents a significant opportunity for Paradigm.
Paradigm Biopharmaceuticals receives ethics approval for trial on knee osteoarthritis
Knee osteoarthritis is a condition with a significant unmet medical need.
Paradigm's Paul Rennie discusses momentum of the Ross River Virus Clinical Trial
The clinical trial is of the drug Pentosan Polysulfate Sodium for the treatment of Ross River virus.
Paradigm Biopharmaceuticals shares continue uptrend on leverage to Pentosan Polysulfate Sodium
PPS is a new multi-acting treatment for hay fever, bone bruising and viral arthritis.
Paradigm Biopharmaceuticals shares jump 75% in morning trade
PPS is a new multi-acting treatment for hay fever, bone bruising and viral arthritis
Paradigm Biopharmaceuticals doses first Ross River participant
The Ross River virus affects hundreds of thousands of people in South Asia each year and there is currently no effective treatment for either disease
Paradigm Biopharmaceuticals Ltd to commence Ross River trial
This will be the company's fourth active clinical trial.
Paradigm Biopharmaceuticals CEO lifts stake over 22%
Paradigm will focus on the Phase 2 Bone Marrow Edema clinical trial.
Paradigm Biopharmaceuticals CEO buys shares on-market
Paul Rennie is a major shareholder in the company.
Paradigm Biopharmaceuticals enters US$18 billion global heart failure market
Paradigm has signed a worldwide exclusive in-license agreement.
Paradigm Biopharmaceuticals receives hay fever update
The company remains on track for its other PPS-related programs.
Paradigm Biopharmaceuticals in a trading halt as news pending
The halt will remain in place until Monday 19th June 2017.
Paradigm Biopharmaceuticals gets approval for Ross River trial
The ethics approval means this is Paradigm's fourth active clinical trial.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
Paul Rennie talked timeline to clinical trial results with investors.
Paradigm Biopharmaceuticals has hay fever study published
Shares in Paradigm are trading up over 50% year to date, priced at $0.59.
Paradigm Biopharmaceuticals receives valuable grant
First dosing in the Phase 2a clinical trial is expected during this quarter.
Paradigm Biopharmaceuticals brings Phase 2 milestone news flow to Spotlight CEO Sessions
Find out more from Paul Rennie at Proactive's CEO Sessions.
The Hydroponics Company brings immediate cash flow to Spotlight CEO Sessions
Find out more from Andrew Beehag at Proactive's CEO Sessions.
Stonewall Resources to showcase near-term gold production at Spotlight CEO Sessions
Find out more from Robert Thomson at Proactive's CEO Sessions.
White Rock Minerals to show case silver-zinc at Spotlight CEO Sessions
Find out more from Matthew Gill at Proactive's CEO Sessions.
Paradigm Biopharmaceuticals treats final patient in hay fever trial
The last patient in a Phase 2 hay fever trial has been treated.
Paradigm Biopharmaceuticals gets cash boost from rebate
Paradigm plans to conduct a clinical trial for Ross River in June 2017.
Paradigm Biopharmaceuticals to test Ross River treatment
Paradigm plans to conduct a clinical trial for Ross River in June 2017.
Paradigm Biopharmaceuticals shines under broker spotlight
Paradigm has been attracting the attention of brokers.
Paradigm Biopharmaceuticals completes recruitment for hay fever trial
Paradigm Biopharmaceuticals (ASX:PAR) has completed the recruitment of all forty subjects in its clinical trial of Rhinosul for hay fever.
Paradigm Biopharmaceuticals Ltd to begin allergic rhinitis trial in Sweden
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received approval from the Swedish Medical Products Authority (MPA) to commence phase 2a allergic rhinitis trial of Rhinosul in Sweden.
Paradigm Biopharmaceuticals heads to market
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has been granted a trading halt by the ASX this morning, pending details of a capital raising.